Ubs Group Ag Lineage Cell Therapeutics, Inc. Transaction History

Ubs Group Ag

$611 Billion
Q3 2025

A detailed history of Ubs Group Ag transactions in Lineage Cell Therapeutics, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 208,080 shares of LCTX stock, worth $395,352. This represents 0.0% of its overall portfolio holdings.

Number of Shares

208,080

Previous 227,600 8.58%

Holding current value

$395,352

Previous $207,000 73.43%

% of portfolio

0.0%

Previous 0.0%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 13, 2025	SELL	$0.87 - $1.79 $16,982 - $34,940	-19,520 Reduced 8.58%	208,080 $359,000
Q2 2025 Aug 14, 2025	SELL	$0.39 - $1.13 $14,163 - $41,038	-36,317 Reduced 13.76%	227,600 $207,000
Q1 2025 May 13, 2025	BUY	$0.45 - $0.72 $19,363 - $30,980	43,029 Added 19.48%	263,917 $118,000
Q4 2024 Feb 14, 2025	BUY	$0.5 - $0.95 $24,728 - $46,984	49,457 Added 28.85%	220,888 $110,000
Q3 2024 Nov 14, 2024	BUY	$0.8 - $1.12 $75,972 - $106,360	94,965 Added 124.19%	171,431 $156,000

Q2 2024 Aug 13, 2024	SELL	$0.89 - $1.47 $56,609 - $93,500	-63,606 Reduced 45.41%	76,466 $76,000
Q1 2024 May 13, 2024	SELL	$0.86 - $1.48 $3,831 - $6,593	-4,455 Reduced 3.08%	140,072 $207,000
Q4 2023 Feb 09, 2024	BUY	$0.91 - $1.35 $83,315 - $123,600	91,556 Added 172.84%	144,527 $157,000
Q3 2023 Nov 09, 2023	SELL	$1.16 - $1.53 $9,356 - $12,340	-8,066 Reduced 13.21%	52,971 $62,000
Q2 2023 Aug 11, 2023	BUY	$1.26 - $1.53 $72,807 - $88,409	57,784 Added 1776.33%	61,037 $86,000
Q1 2023 May 12, 2023	SELL	$1.2 - $1.53 $8,703 - $11,097	-7,253 Reduced 69.04%	3,253 $4,000
Q4 2022 Feb 08, 2023	BUY	$1.02 - $1.5 $9,388 - $13,806	9,204 Added 706.91%	10,506 $12,000
Q3 2022 Nov 10, 2022	SELL	$1.13 - $1.77 $11,433 - $17,908	-10,118 Reduced 88.6%	1,302 $1,000
Q2 2022 Aug 10, 2022	BUY	$1.12 - $1.61 $11,789 - $16,946	10,526 Added 1177.4%	11,420 $18,000
Q1 2022 May 16, 2022	SELL	$1.21 - $2.48 $47,235 - $96,814	-39,038 Reduced 97.76%	894 $1,000
Q4 2021 Feb 14, 2022	SELL	$1.84 - $2.68 $308,696 - $449,623	-167,770 Reduced 80.77%	39,932 $97,000
Q3 2021 Nov 15, 2021	BUY	$2.26 - $2.86 $459,132 - $581,026	203,156 Added 4468.9%	207,702 $523,000
Q2 2021 Aug 13, 2021	SELL	$2.17 - $3.0 $6,056 - $8,373	-2,791 Reduced 38.04%	4,546 $13,000
Q1 2021 May 12, 2021	SELL	$1.77 - $3.1 $30,559 - $53,521	-17,265 Reduced 70.18%	7,337 $17,000
Q4 2020 Feb 11, 2021	BUY	$0.95 - $1.83 $22,308 - $42,973	23,483 Added 2098.57%	24,602 $44,000
Q3 2020 Nov 12, 2020	SELL	$0.75 - $1.09 $178 - $259	-238 Reduced 17.54%	1,119 $1,000
Q2 2020 Jul 31, 2020	SELL	$0.71 - $1.18 $49,386 - $82,079	-69,559 Reduced 98.09%	1,357 $1,000
Q1 2020 May 01, 2020	SELL	$0.6 - $1.58 $50,998 - $134,295	-84,997 Reduced 54.52%	70,916 $59,000
Q4 2019 Feb 14, 2020	BUY	$0.54 - $1.01 $39,063 - $73,063	72,340 Added 86.56%	155,913 $139,000
Q3 2019 Nov 14, 2019	BUY	$0.85 - $1.24 $71,037 - $103,630	83,573 New	83,573 $82,000

Others Institutions Holding LCTX

# of Institutions

128

Shares Held

96M

Call Options Held

251K

Put Options Held

50K

View Full List

About Lineage Cell Therapeutics, Inc.

Ticker LCTX
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 169,755,008
Market Cap $323M
Description
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...

More about LCTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account